Nanoparticle-Based ARV Drug Combinations for Synergistic Inhibition of Cell-Free and Cell-Cell HIV Transmission

Molecular Pharmaceutics

Volumn 12, Issue 12, 2015, Pages 4363-4374

  Jiang, Yonghou ^a   Cao, Shijie ^a   Bright, Danielle K ^b   Bever, Alaina M ^b   Blakney, Anna K ^a   Suydam, Ian T ^b   Woodrow, Kim A ^a  

^a University of Washington   (United States)

^b SEATTLE UNIVERSITY   (United States)

Author keywords

antiretroviral therapy and prophylaxis; ARV combination; drug delivery; HIV; nanoparticles

Indexed keywords

ETRAVIRINE; MARAVIROC; NANOCARRIER; POLYGLACTIN; RALTEGRAVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; DRUG CARRIER; DRUG COMBINATION; LACTIC ACID; NANOPARTICLE; POLYGLYCOLIC ACID; POLYLACTIC ACID-POLYGLYCOLIC ACID COPOLYMER; RNA DIRECTED DNA POLYMERASE;

ANIMAL CELL; ANIMAL TISSUE; ANTIVIRAL ACTIVITY; ARTICLE; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DRUG ACTIVITY; DRUG CONCENTRATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENCY; DRUG RELEASE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IN VITRO STUDY; INTRACELLULAR SIGNALING; MACACA; NANOENCAPSULATION; NANOPHARMACEUTICS; NONHUMAN; PRIORITY JOURNAL; VIRUS INHIBITION; VIRUS TRANSMISSION; ANIMAL; CHEMISTRY; DRUG COMBINATION; DRUG DELIVERY SYSTEM; DRUG EFFECTS; HIV INFECTIONS; PROCEDURES;

ANIMALS; ANTI-HIV AGENTS; DRUG CARRIERS; DRUG COMBINATIONS; DRUG DELIVERY SYSTEMS; HIV INFECTIONS; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; LACTIC ACID; MACACA; NANOPARTICLES; POLYGLYCOLIC ACID;

EID: 84949036020     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/acs.molpharmaceut.5b00544     Document Type: Article

References (52)

1. Pirrone, V.; Thakkar, N.; Jacobson, J. M.; Wigdahl, B.; Krebs, F. C. Combinatorial Approaches to the Prevention and Treatment of HIV-1 Infection Antimicrob. Agents Chemother. 2011, 55 (5) 1831-1842 10.1128/AAC.00976-10
2. Zhong, P.; Agosto, L. M.; Ilinskaya, A.; Dorjbal, B.; Truong, R.; Derse, D.; Uchil, P. D.; Heidecker, G.; Mothes, W. Cell-to-Cell Transmission Can Overcome Multiple Donor and Target Cell Barriers Imposed on Cell-Free HIV PLoS One 2013, 8 (1) e53138 10.1371/journal.pone.0053138
3. Kolodkin-Gal, D.; Hulot, S. L.; Korioth-Schmitz, B.; Gombos, R. B.; Zheng, Y.; Owuor, J.; Lifton, M. A.; Ayeni, C.; Najarian, R. M.; Yeh, W. W.; Asmal, M.; Zamir, G.; Letvin, N. L. Efficiency of Cell-Free and Cell-Associated Virus in Mucosal Transmission of Human Immunodeficiency Virus Type 1 and Simian Immunodeficiency Virus J. Virol. 2013, 87 (24) 13589-13597 10.1128/JVI.03108-12
4. Shahiwala, A.; Amiji, M. M. Nanotechnology-based delivery systems in HIV/AIDS therapy Future HIV Ther. 2007, 1 (1) 49-59 10.2217/17469600.1.1.49
5. das Neves, J.; Amiji, M. M.; Bahia, M. F.; Sarmento, B. Nanotechnology-based systems for the treatment and prevention of HIV/AIDS Adv. Drug Delivery Rev. 2010, 62 (4-5) 458-477 10.1016/j.addr.2009.11.017
6. Freeling, J. P.; Koehn, J.; Shu, C.; Sun, J.; Ho, R. J. Y. Long-acting three-drug combination anti-HIV nanoparticles enhance drug exposure in primate plasma and cells within lymph nodes and blood AIDS 2014, 28 (17) 2625-2627 10.1097/QAD.0000000000000421
7. Shibata, A.; McMullen, E.; Pham, A.; Belshan, M.; Sanford, B.; Zhou, Y.; Goede, M.; Date, A. A.; Destache, C. J. Polymeric Nanoparticles Containing Combination Antiretroviral Drugs for HIV Type 1 Treatment AIDS Res. Hum. Retroviruses 2013, 29 (5) 746-754 10.1089/aid.2012.0301
8. Lisziewicz, J.; Toke, E. R. Nanomedicine applications towards the cure of HIV Nanomedicine 2013, 9 (1) 28-38 10.1016/j.nano.2012.05.012
9. Makadia, H. K.; Siegel, S. J. Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier Polymers 2011, 3 (3) 1377-1397 10.3390/polym3031377
10. Shen, L.; Peterson, S.; Sedaghat, A. R.; McMahon, M. A.; Callender, M.; Zhang, H.; Zhou, Y.; Pitt, E.; Anderson, K. S.; Acosta, E. P.; Siliciano, R. F. Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs Nat. Med. 2008, 14 (7) 762-766 10.1038/nm1777
11. Jilek, B. L.; Zarr, M.; Sampah, M. E.; Rabi, S. A.; Bullen, C. K.; Lai, J.; Shen, L.; Siliciano, R. F. A quantitative basis for antiretroviral therapy for HIV-1 infection Nat. Med. 2012, 18 (3) 446-451 10.1038/nm.2649
12. Sampah, M. E. S.; Shen, L.; Jilek, B. L.; Siliciano, R. F. Dose-response curve slope is a missing dimension in the analysis of HIV-1 drug resistance Proc. Natl. Acad. Sci. U. S. A. 2011, 108 (18) 7613-7618 10.1073/pnas.1018360108
13. Van Der Ryst, E. Maraviroc-A CCR5 Antagonist for the Treatment of HIV-1 Infection Front. Immunol. 2015, 6, 277 10.3389/fimmu.2015.00277
14. Malcolm, R. K.; Forbes, C. J.; Geer, L.; Veazey, R. S.; Goldman, L.; Johan Klasse, P.; Moore, J. P. Pharmacokinetics and efficacy of a vaginally administered maraviroc gel in rhesus macaques J. Antimicrob. Chemother. 2013, 68 (3) 678-683 10.1093/jac/dks422
15. Blanco, J. L.; Whitlock, G.; Milinkovic, A.; Moyle, G. HIV integrase inhibitors: a new era in the treatment of HIV Expert Opin. Pharmacother. 2015, 16 (9) 1313-1324 10.1517/14656566.2015.1044436
16. Emery, S.; Winston, A. Raltegravir: a new choice in HIV and new chances for research Lancet 2009, 374 (9692) 764-766 10.1016/S0140-6736(09)61392-1
17. Dobard, C.; Sharma, S.; Parikh, U. M.; West, R.; Taylor, A.; Martin, A.; Pau, C.-P.; Hanson, D. L.; Lipscomb, J.; Smith, J.; Novembre, F.; Hazuda, D.; Garcia-Lerma, J. G.; Heneine, W. Postexposure Protection of Macaques from Vaginal SHIV Infection by Topical Integrase Inhibitors Sci. Transl. Med. 2014, 6, 227ra35-227ra35 10.1126/scitranslmed.3007701
18. Joshi, S.; Maikap, G. C.; Titirmare, S.; Chaudhari, A.; Gurjar, M. K. An Improved Synthesis of Etravirine Org. Process Res. Dev. 2010, 14 (3) 657-660 10.1021/op9003289
19. Zhao, G.-L.; Lin, S.; Korotvička, A.; Deiana, L.; Kullberg, M.; Córdova, A. Asymmetric Synthesis of Maraviroc (UK-427,857) Adv. Synth. Catal. 2010, 352 (13) 2291-2298 10.1002/adsc.201000287
20. Summa, V.; Petrocchi, A.; Bonelli, F.; Crescenzi, B.; Donghi, M.; Ferrara, M.; Fiore, F.; Gardelli, C.; Gonzalez Paz, O.; Hazuda, D. J.; Jones, P.; Kinzel, O.; Laufer, R.; Monteagudo, E.; Muraglia, E.; Nizi, E.; Orvieto, F.; Pace, P.; Pescatore, G.; Scarpelli, R.; Stillmock, K.; Witmer, M. V.; Rowley, M. Discovery of Raltegravir, a Potent, Selective Orally Bioavailable HIV-Integrase Inhibitor for the Treatment of HIV-AIDS Infection J. Med. Chem. 2008, 51 (18) 5843-5855 10.1021/jm800245z
21. Rao, K. S.; Reddy, M. K.; Horning, J. L.; Labhasetwar, V. TAT-conjugated nanoparticles for the CNS delivery of anti-HIV drugs Biomaterials 2008, 29 (33) 4429-4438 10.1016/j.biomaterials.2008.08.004
22. Notari, S.; Tommasi, C.; Nicastri, E.; Bellagamba, R.; Tempestilli, M.; Pucillo, L. P.; Narciso, P.; Ascenzi, P. Simultaneous determination of maraviroc and raltegravir in human plasma by HPLC-UV IUBMB Life 2009, 61 (4) 470-475 10.1002/iub.181
23. Hirano, A.; Takahashi, M.; Kinoshita, E.; Shibata, M.; Nomura, T.; Yokomaku, Y.; Hamaguchi, M.; Sugiura, W. High Performance Liquid Chromatography Using UV Detection for the Simultaneous Quantification of the New Non-nucleoside Reverse Transcriptase Inhibitor Etravirine (TMC-125), and 4 Protease Inhibitors in Human Plasma Biol. Pharm. Bull. 2010, 33 (8) 1426-1429 10.1248/bpb.33.1426
24. Margolis, L.; Shattock, R. Selective transmission of CCR5-utilizing HIV-1: the 'gatekeeper' problem resolved? Nat. Rev. Microbiol. 2006, 4 (4) 312-317 10.1038/nrmicro1387
25. Laird, G. M.; Bullen, C. K.; Rosenbloom, D. I. S.; Martin, A. R.; Hill, A. L.; Durand, C. M.; Siliciano, J. D.; Siliciano, R. F. Ex vivo analysis identifies effective HIV-1 latency-reversing drug combinations J. Clin. Invest. 2015, 125 (5) 1901-1912 10.1172/JCI80142
26. Lai, S. K.; Wang, Y.-Y.; Hida, K.; Cone, R.; Hanes, J. Nanoparticles reveal that human cervicovaginal mucus is riddled with pores larger than viruses Proc. Natl. Acad. Sci. U. S. A. 2010, 107 (2) 598-603 10.1073/pnas.0911748107
27. Ensign, L. M.; Tang, B. C.; Wang, Y.-Y.; Tse, T. A.; Hoen, T.; Cone, R.; Hanes, J. Mucus-Penetrating Nanoparticles for Vaginal Drug Delivery Protect Against Herpes Simplex Virus Sci. Transl. Med. 2012, 4 (138) 138ra79-138ra79 10.1126/scitranslmed.3003453
28. das Neves, J.; Araújo, F.; Andrade, F.; Amiji, M.; Bahia, M.; Sarmento, B. Biodistribution and Pharmacokinetics of Dapivirine-Loaded Nanoparticles after Vaginal Delivery in Mice Pharm. Res. 2014, 31 (7) 1834-1845 10.1007/s11095-013-1287-x
29. Schiffner, T.; Sattentau, Q. J.; Duncan, C. J. A. Cell-to-cell spread of HIV-1 and evasion of neutralizing antibodies Vaccine 2013, 31 (49) 5789-5797 10.1016/j.vaccine.2013.10.020
30. Calcagno, A.; Nozza, S.; Bonora, S.; Castagna, A.; Gonzalez de Requena, D.; D'Avolio, A.; Lazzarin, A.; Di Perri, G. Pharmacokinetics of the raltegravir/maraviroc/etravirine combination J. Antimicrob. Chemother. 2011, 66, 1932-1934 10.1093/jac/dkr219
31. Nozza, S.; Galli, L.; Bigoloni, A.; Nicola, G.; Pogliaghi, M.; Cossarini, F.; Salpietro, S.; Galli, A.; Torre, L. D.; Tambussi, G.; Lazzarin, A.; Castagna, A. Durability and Safety of a Novel Salvage Therapy in R5-Tropic HIV-Infected Patients: Maraviroc, Raltegravir, Etravirine JAIDS, J. Acquired Immune Defic. Syndr. 2011, 56 (4) e113-e115 10.1097/QAI.0b013e31820a9ae4
32. Khanlou, H.; Sayana, S. Efficacy and Tolerability of RAL, MVC and ETV used in combination in the treatment of highly treatment experienced HIV infected patients Retrovirology 2010, 7 (Suppl 1) P48-P48 10.1186/1742-4690-7-S1-P48
33. Achhra, A. C.; Boyd, M. A. Antiretroviral regimens sparing agents from the nucleoside(tide) reverse transcriptase inhibitor class: a review of the recent literature AIDS Res. Ther. 2013, 10, 33-33 10.1186/1742-6405-10-33
34. Pavillard, V.; Kherfellah, D.; Richard, S.; Robert, J.; Montaudon, D. Effects of the combination of camptothecin and doxorubicin or etoposide on rat glioma cells and camptothecin-resistant variants Br. J. Cancer 2001, 85 (7) 1077-1083 10.1054/bjoc.2001.2027
35. Tardi, P.; Johnstone, S.; Harasym, N.; Xie, S.; Harasym, T.; Zisman, N.; Harvie, P.; Bermudes, D.; Mayer, L. In vivo maintenance of synergistic cytarabine:daunorubicin ratios greatly enhances therapeutic efficacy Leuk. Res. 2009, 33 (1) 129-139 10.1016/j.leukres.2008.06.028
36. Meng, H.; Wang, M.; Liu, H.; Liu, X.; Situ, A.; Wu, B.; Ji, Z.; Chang, C. H.; Nel, A. E. Use of a Lipid-Coated Mesoporous Silica Nanoparticle Platform for Synergistic Gemcitabine and Paclitaxel Delivery to Human Pancreatic Cancer in Mice ACS Nano 2015, 9 (4) 3540-3557 10.1021/acsnano.5b00510
37. Blanco, E.; Sangai, T.; Wu, S.; Hsiao, A.; Ruiz-Esparza, G. U.; Gonzalez-Delgado, C. A.; Cara, F. E.; Granados-Principal, S.; Evans, K. W.; Akcakanat, A.; Wang, Y.; Do, K.-A.; Meric-Bernstam, F.; Ferrari, M. Colocalized Delivery of Rapamycin and Paclitaxel to Tumors Enhances Synergistic Targeting of the PI3K/Akt/mTOR Pathway Mol. Ther. 2014, 22 (7) 1310-1319 10.1038/mt.2014.27
38. Nowacek, A.; McMillan, J.; Miller, R.; Anderson, A.; Rabinow, B.; Gendelman, H. Nanoformulated Antiretroviral Drug Combinations Extend Drug Release and Antiretroviral Responses in HIV-1-Infected Macrophages: Implications for NeuroAIDS Therapeutics J. Neuroimmune Pharmacol. 2010, 5 (4) 592-601 10.1007/s11481-010-9198-7
39. Nowacek, A. S.; Balkundi, S.; McMillan, J.; Roy, U.; Martinez-Skinner, A.; Mosley, R. L.; Kanmogne, G.; Kabanov, A. V.; Bronich, T.; Gendelman, H. E. Analyses of Nanoformulated Antiretroviral Drug Charge, Size, Shape and Content for Uptake, Drug Release and Antiviral Activities in Human Monocyte-Derived Macrophages J. Controlled Release 2011, 150 (2) 204-211 10.1016/j.jconrel.2010.11.019
40. Chono, S.; Tanino, T.; Seki, T.; Morimoto, K. Uptake characteristics of liposomes by rat alveolar macrophages: influence of particle size and surface mannose modification J. Pharm. Pharmacol. 2007, 59 (1) 75-80 10.1211/jpp.59.1.0010
41. Kim, J. A.; Aberg, C.; Salvati, A.; Dawson, K. A. Role of cell cycle on the cellular uptake and dilution of nanoparticles in a cell population Nat. Nanotechnol. 2012, 7 (1) 62-68 10.1038/nnano.2011.191
42. Chou, T. C. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies Pharmacol Rev. 2006, 58 (3) 621-681 10.1124/pr.58.3.10
43. Loewe, S.; Muischnek, H. Effect of combinations: mathematical basis of problem Naunyn-Schmiedeberg's Arch. Pharmacol. 1926, 114, 313-326 10.1007/BF01952257
44. Greco, W. R.; Bravo, G.; Parsons, J. C. The Search for Synergy-a Critical-Review from a Response-Surface Perspective Pharmacol Rev. 1995, 47 (2) 331-385
45. Federico, C.; Morittu, V. M.; Britti, D.; Trapasso, E.; Cosco, D. Gemcitabine-loaded liposomes: rationale, potentialities and future perspectives Int. J. Nanomed. 2012, 7, 5423-5436 10.2147/IJN.S34025
46. Barreto-de-Souza, V.; Arakelyan, A.; Margolis, L.; Vanpouille, C. HIV-1 Vaginal Transmission: Cell-Free or Cell-Associated Virus? Am. J. Reprod. Immunol. 2014, 71 (6) 589-599 10.1111/aji.12240
47. Shattock, R.; Moore, J. Inhibiting sexual transmission of HIV-1 infection Nat. Rev. Microbiol. 2003, 1 (1) 25-34 10.1038/nrmicro729
48. Barre-Sinoussi, F. Cell-Associated Mucosal HIV Transmission J. Infect. Dis. 2014, 210 (suppl 3) S605 10.1093/infdis/jiu545
49. Costiniuk, C. T.; Jenabian, M.-A. Cell-to-cell transfer of HIV infection: implications for HIV viral persistence J. Gen. Virol. 2014, 95, 2346-2355 10.1099/vir.0.069641-0
50. Whaley, K. J.; Mayer, K. H. Strategies for Preventing Mucosal Cell-Associated HIV Transmission J. Infect. Dis. 2014, 210 (suppl 3) S674-S680 10.1093/infdis/jiu398
51. Pritchard, J. R.; Bruno, P. M.; Gilbert, L. A.; Capron, K. L.; Lauffenburger, D. A.; Hemann, M. T. Defining principles of combination drug mechanisms of action Proc. Natl. Acad. Sci. U. S. A. 2013, 110 (2) E170-E179 10.1073/pnas.1210419110
52. Ball, C.; Krogstad, E.; Chaowanachan, T.; Woodrow, K. A. Woodrow, K. A. Drug-Eluting Fibers for HIV-1 Inhibition and Contraception PLoS One 2012, 7 (11) e49792 10.1371/journal.pone.0049792